அணு மருத்துவம் & கதிர்வீச்சு சிகிச்சை

The Development of FMTVDM-BEST IMAGING©℗: The Answer for Breast Cancer. Breast Enhanced Scintigraphy Test (BEST©℗): Quantifying the Detection of Breast Cancer and its Treatment.

Abstract

Richard M Fleming, William C Dooley, Tapan K Chaudhuri

Background: The diagnostic testing for breast cancer has been limited by the absence of a method, which can quantitatively differentiate tissue differences; specifically differentiation between calcium deposits, normal breast tissue, inflammatory changes in breast tissue and breast cancer. Such a quantitative method would remove the issue of sensitivity and specificity errors and allow for diagnostic decision-making including treatment monitoring.
Method: A series of investigations were conducted over an 18-year period of time looking at more than 1000 women and men suspected of having breast tissue abnormalities. The studies compared pathologic tissue results with outcomes using other diagnostic studies and FMTVDM-BEST©�?? Imaging. The studies began with asking the fundamental questions necessary to produce such a quantitative diagnostic test, followed by correcting for errors encountered by other methods. Following the initial work comparing FMTVDM-BEST©�?? Imaging with other tests and tissue pathology results, the investigations turned to monitoring changes in women over time, demonstrating the ability to monitor treatment results from surgery, chemotherapy, radiation therapy, immune therapy, diet and lifestyle changes. Further work was conducted to assure that the time within a woman’s cycle did not affect FMTVDM-BEST©�?? Imaging. The next series of studies looked at the effect that soy protein, smoking and hormone treatment (HRT) had on breast tissue health and the relationship between breast cancer and these influences. The summation of all of these studies included looking at breast density and breast implants as well as male patients.
Results: FMTVDM-BEST©�?? Imaging quantitatively differentiates between breast calcium deposits, normal breast tissue, inflammatory changes and breast cancer. It can monitor transitions in tissue showing both the progression and regression of disease allowing clinicians to monitor treatment outcomes independent of the treatment approach used. FMTVDM-BEST©�?? Imaging is not affected by breast density, breast implants, mastectomy or size of breast; including male patients. : FMTVDM-BEST©�?? Imaging provides the first and only quantitative method, which can differentiate tissues based upon changes in measurements obtained from this patented method. As such, it can detect changes in tissue leading to breast cancer allowing for greater treatment opportunities, as well as monitoring outcomes of treatment for breast cancer and other abnormalities (e.g. fibrocystic disease). FMTVDM-BEST©�?? Imaging works independent of whether the patient has dense breast tissue, breast implants, is on HRT, smokes or has undergone previous treatment in both men and women.